Induction of microsomal enzymes by this drug, may possibly shorten the 50 %-life of doxycycline for as long as 2 weeks immediately after barbiturate therapy discontinued; watch clinical response to doxycycline closely if equally drugs administered concurrently
pentobarbital will minimize the level or outcome of eletriptan by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
Observe Closely (1)pentobarbital will minimize the level or influence of levamlodipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lessen the extent or outcome of alprazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
CYP3A4 inducers may well raise the development with the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Intently monitor patients taking ifosfamide with CYP3A4 inducers for toxicities and contemplate dose adjustment.
pentobarbital will lower the level or impact of fentanyl intranasal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Carefully. Coadministration of fentanyl with CYP3A4 inducers may lead to your lessen in fentanyl plasma concentrations, lack of efficacy or, probably, development of a withdrawal syndrome in a very patient who has developed Bodily dependence to fentanyl.
pentobarbital will decrease the extent or impact of amlodipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
lasmiditan, pentobarbital. Possibly will increase effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, like Alcoholic beverages have not been evaluated in medical research. Lasmiditan may well trigger sedation, together with other cognitive and/or neuropsychiatric adverse reactions.
pentobarbital will decrease the extent or influence of docetaxel by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unknown.
Barbiturates can result in fetal damage when administered to the pregnant girl; retrospective, circumstance-controlled scientific studies have advised a relationship among maternal use of barbiturates here and an increased-than-expected incidence of fetal abnormalities
Contraindicated (1)pentobarbital will reduce the extent or influence of lorlatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
Use another technique of contraception or even a backup method when enzyme inducers are applied with combined hormonal contraceptives (CHCs), and proceed backup contraception for 28 times after discontinuing enzyme inducer to make certain contraceptive dependability.
pentobarbital will minimize the extent or result of fedratinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Keep away from or Use Alternate Drug. Result of coadministering a powerful CYP3A4 inducer with fedratinib hasn't been analyzed.
pentobarbital will decrease the level or outcome of ramelteon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.